EGFR and breast cancer: Whether ESB attenuates cell growth and triggers apoptosis in other cancer cell types with EGFR TKI resistance, such as pancreatic and breast cancer cells, is also an important issue in predicting the possibility of applying ESB to various cancer types [40].